$0.97
+0.04
(+4.59%)▲
2.66%
Downside
Day's Volatility :5.27%
Upside
2.68%
32.98%
Downside
52 Weeks Volatility :69.33%
Upside
54.25%
Period | Clearside Biomedical Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -20.49% | 5.1% | 0.0% |
6 Months | -41.92% | 4.9% | 0.0% |
1 Year | 14.12% | 16.6% | 0.0% |
3 Years | -85.3% | 13.2% | -22.3% |
Market Capitalization | 72.5M |
Book Value | - $0.38 |
Earnings Per Share (EPS) | -0.5 |
PEG Ratio | 0.0 |
Wall Street Target Price | 5.57 |
Profit Margin | 0.0% |
Operating Margin TTM | -8433.33% |
Return On Assets TTM | -44.05% |
Return On Equity TTM | -1310.02% |
Revenue TTM | 7.5M |
Revenue Per Share TTM | 0.11 |
Quarterly Revenue Growth YOY | -91.2% |
Gross Profit TTM | 1.1M |
EBITDA | -25.7M |
Diluted Eps TTM | -0.5 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.5 |
EPS Estimate Next Year | -0.52 |
EPS Estimate Current Quarter | -0.13 |
EPS Estimate Next Quarter | -0.13 |
What analysts predicted
Upside of 474.23%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 30.0K | ↓ 91.3% |
Net Income | -82.8M | ↑ 40.43% |
Net Profit Margin | -276.1K% | ↓ 258965.8% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 2.2M | ↑ 7143.33% |
Net Income | -30.6M | ↓ 63.1% |
Net Profit Margin | -1.4K% | ↑ 274653.7% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 7.9M | ↑ 263.28% |
Net Income | -18.0M | ↓ 41.0% |
Net Profit Margin | -228.4% | ↑ 1177.9% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 29.6M | ↑ 274.65% |
Net Income | 376.0K | ↓ 102.09% |
Net Profit Margin | 1.27% | ↑ 229.67% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.3M | ↓ 95.51% |
Net Income | -34.1M | ↓ 9161.53% |
Net Profit Margin | -2.6K% | ↓ 2568.82% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 8.2M | ↑ 519.89% |
Net Income | -32.5M | ↓ 4.66% |
Net Profit Margin | -394.91% | ↑ 2172.64% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.0K | ↓ 98.79% |
Net Income | -13.1M | ↑ 52.78% |
Net Profit Margin | -328.1K% | ↓ 325447.37% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.0M | ↑ 25350.0% |
Net Income | -9.1M | ↓ 30.61% |
Net Profit Margin | -894.5% | ↑ 327155.5% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 859.0K | ↓ 15.62% |
Net Income | -9.3M | ↑ 1.77% |
Net Profit Margin | -1.1K% | ↓ 184.31% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 6.3M | ↑ 638.65% |
Net Income | -4.8M | ↓ 47.86% |
Net Profit Margin | -76.15% | ↑ 1002.66% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 230.0K | ↓ 96.38% |
Net Income | -11.8M | ↑ 143.44% |
Net Profit Margin | -5.1K% | ↓ 5038.2% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 90.0K | ↓ 60.87% |
Net Income | -7.6M | ↓ 35.44% |
Net Profit Margin | -8.4K% | ↓ 3323.43% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 44.1M | ↑ 8.96% |
Total Liabilities | 20.5M | ↑ 7.45% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 26.8M | ↓ 39.31% |
Total Liabilities | 15.6M | ↓ 23.81% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 19.3M | ↓ 27.84% |
Total Liabilities | 10.6M | ↓ 32.4% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 42.9M | ↑ 122.04% |
Total Liabilities | 4.9M | ↓ 53.33% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 51.3M | ↑ 19.58% |
Total Liabilities | 40.7M | ↑ 725.81% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 34.0M | ↓ 33.69% |
Total Liabilities | 49.9M | ↑ 22.69% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 44.7M | ↓ 12.88% |
Total Liabilities | 42.0M | ↑ 3.19% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 39.2M | ↓ 12.33% |
Total Liabilities | 44.2M | ↑ 5.15% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 34.4M | ↓ 12.16% |
Total Liabilities | 47.3M | ↑ 7.05% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 34.0M | ↓ 1.17% |
Total Liabilities | 49.9M | ↑ 5.63% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 40.1M | ↑ 18.0% |
Total Liabilities | 62.0M | ↑ 24.08% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 33.9M | ↓ 15.47% |
Total Liabilities | 62.2M | ↑ 0.43% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -79.2M | ↑ 55.04% |
Investing Cash Flow | -3.8M | ↓ 118.69% |
Financing Cash Flow | 81.8M | ↑ 1425.16% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -27.1M | ↓ 65.82% |
Investing Cash Flow | 32.9M | ↓ 975.66% |
Financing Cash Flow | 8.7M | ↓ 89.37% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -13.1M | ↓ 51.53% |
Investing Cash Flow | -55.0K | ↓ 100.17% |
Financing Cash Flow | 7.9M | ↓ 9.52% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -10.7M | ↓ 18.19% |
Investing Cash Flow | -246.0K | ↑ 347.27% |
Financing Cash Flow | 23.8M | ↑ 202.3% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -13.4M | ↑ 24.52% |
Investing Cash Flow | -246.0K | ↑ 0.0% |
Financing Cash Flow | 31.3M | ↑ 31.75% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -7.2M | ↑ 28.7% |
Investing Cash Flow | -115.0K | ↑ 26.37% |
Financing Cash Flow | 332.0K | ↓ 42.26% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.3M | ↓ 26.01% |
Investing Cash Flow | -1.1M | ↑ 853.91% |
Financing Cash Flow | 22.0K | ↓ 93.37% |
Sell
Neutral
Buy
Clearside Biomedical Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Clearside Biomedical Inc | -5.83% | -41.92% | 14.12% | -85.3% | -82.4% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Clearside Biomedical Inc | 133.0 | NA | 0.0 | -0.5 | -13.1 | -0.44 | NA | -0.38 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Clearside Biomedical Inc | Buy | $72.5M | -82.4% | 133.0 | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Clearside Biomedical Inc
Revenue is down for the last 3 quarters, 6.34M → 90.0K (in $), with an average decrease of 78.6% per quarter
Netprofit is up for the last 2 quarters, -11.76M → -7.59M (in $), with an average increase of 54.9% per quarter
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 23.0%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 154.5%
Vanguard Group Inc
Rosalind Advisors, Inc.
Armistice Capital, LLC
Carmignac Gestion
BlackRock Inc
Geode Capital Management, LLC
clearside biomedical, inc. is a pharmaceuticals company located in 1220 old alpharetta rd., suite 300, alpharetta, ga, united states.
Organization | Clearside Biomedical Inc |
Employees | 30 |
CEO | Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$0.97
+4.59%
Keyarch Acquisition Corp
$0.97
+4.59%
Connexa Sports Technologies Inc
$0.97
+4.59%
Us Value Etf
$0.97
+4.59%
First Wave Biopharma Inc
$0.97
+4.59%
Global X Msci Next Emerging
$0.97
+4.59%
Fat Projects Acquisition Corp
$0.97
+4.59%
Capital Link Global Fintech
$0.97
+4.59%
Applied Uv Inc
$0.97
+4.59%